Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors

被引：0
|
作者：
Carol H. Wysham
Patrick Lefebvre
Dominic Pilon
Mike Ingham
Marie-Hélène Lafeuille
Bruno Emond
Rhiannon Kamstra
Wing Chow
Michael Pfeifer
Mei Sheng Duh
机构：
[1] Rockwood Clinic,
[2] Groupe d’analyse,undefined
[3] Ltée,undefined
[4] Janssen Scientific Affairs,undefined
[5] LLC,undefined
[6] Johnson & Johnson,undefined
[7] Analysis Group,undefined
[8] Inc.,undefined
来源：
BMC Endocrine Disorders | / 17卷
关键词：
Canagliflozin; Type 2 diabetes mellitus; Dipeptidyl peptidase-4 inhibitor; HbA1c; Blood pressure; Weight loss;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors
    Wysham, Carol H.
    Lefebvre, Patrick
    Pilon, Dominic
    Ingham, Mike
    Lafeuille, Marie-Helene
    Emond, Bruno
    Kamstra, Rhiannon
    Chow, Wing
    Pfeifer, Michael
    Duh, Mei Sheng
    BMC ENDOCRINE DISORDERS, 2017, 17
  • [2] Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors
    Yang, Tzu-Lin
    Shen, Mei-Chiou
    Yu, Ming-Lung
    Huang, Yaw-Bin
    Chen, Chung-Yu
    JOURNAL OF FOOD AND DRUG ANALYSIS, 2016, 24 (02) : 450 - 454
  • [3] Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus
    Neumiller, Joshua J.
    Wood, Lindy
    Campbell, R. Keith
    PHARMACOTHERAPY, 2010, 30 (05): : 463 - 484
  • [4] Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
    Esaki, Hiroki
    Tachi, Tomoya
    Goto, Chitoshi
    Sugita, Ikuto
    Kanematsu, Yuta
    Yoshida, Aki
    Saito, Kosuke
    Noguchi, Yoshihiro
    Ohno, Yuki
    Aoyama, Satoshi
    Yasuda, Masahiro
    Mizui, Takashi
    Yamamura, Masumi
    Teramachi, Hitomi
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [5] Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors
    Thayer, Sarah
    Chow, Wing
    Korrer, Stephanie
    Aguilar, Richard
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (06) : 1087 - 1096
  • [6] The Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus: Cardiovascular Safety
    Green, Jennifer B.
    POSTGRADUATE MEDICINE, 2012, 124 (04) : 54 - 61
  • [7] Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus
    不详
    JOURNAL OF DIABETES, 2009, 1 (01) : 6 - 7
  • [8] Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
    Lin, Yi-Hsin
    Huang, Hsuan
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2019, 12 : 2725 - 2733
  • [9] Effect of dipeptidyl peptidase-4 inhibitors on fat metabolism in patients with type 2 diabetes mellitus
    Ametov, A. S.
    Gusenbekova, D. G.
    TERAPEVTICHESKII ARKHIV, 2014, 86 (08) : 85 - 89
  • [10] Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Health in Patients with Type 2 Diabetes Mellitus
    Lee, Dong-Hwa
    Kim, Kyong Young
    Yoo, Min Young
    Moon, Hansol
    Ku, Eu Jeong
    Oh, Tae Keun
    Jeon, Hyun Jeong
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (20)
12345